GlobeNewswire Inc | Nov 22, 2021 08:00AM EST

November 22, 2021

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rdAnnual Virtual Healthcare Conference, being held on November 29-December 2, 2021.

The pre-recorded presentation will be available to participants during the conference and on the Events page of the Investor & Media section of the Companys website www.cuebiopharma.com beginning today, November 22, 2021 at 10:00 a.m. EST. An archived version of the recording will be accessible for 90 days following the event.

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visitwww.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate DevelopmentCue Biopharma, Inc.gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com